Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.
Thomas LeBlanc, MD
Advertisement
Articles by Thomas LeBlanc, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5